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S164 Oral PresentationsResults: In the related group we observed 8 graft failures (GF): 5
pts had an HLA identical sibling (HLA id sib) donor and 3 had
other related (OR) donors. In this group, 3 pts had primary GF
and received a 2nd HSCT, but just one is alive. Five pts had second-
ary GF, in a median of 149 days (156-365) after the first transplant.
Three had HLA id sib and two OR donors. Four pts received a 2nd
HSCT using the same donor and 2 are alive. In the unrelated
group we had 11 BM transplants (10pts had primary GF and one
had a secondary GF) and 12 UCB transplants (all pts had primary
GF). Only one pt in this group is alive after 2nd transplant (BM). In
univariate analysis, the variables that influenced the cumulative in-
cidence (CI) of GF were the use of unrelated versus related donor
(30  10%) and transfusions (. 25 units) 30% x 6% The use of
fludarabine was associated with lower CI of GF in the unrelated
group.
Conclusions: Graft failure is a very serious complication after
HSCT and in this study, it was more frequently associated with
the use of unrelated mismatched donors, more transfunded pts and
without fludarabine in the conditioning in the group of UD.New
conditionings and reduction in time to find an unrelated donor
may be alternatives to reduce GF in FA patients.26
SAFETY AND CLINICAL EFFICACY OF EARLY VACCINATION AFTER NON-
MYELOABLATIVE TRANSPLANT FOR ADVANCED CHRONIC LYMPHO-
CYTIC LEUKEMIA
Wu, C.J.1,3, Hainz, U.3, Stevenson, K.E.2, Goldstein, N.P.1,
Brusic, A.M.3, Choi, J.J.3, Pasek, M.1, Brown, J.R.1,
Canning, C.M.1,3, Armand, P.J.1, Koreth, J.1, Cutler, C.1,
Soiffer, R.J.1, Sasada, T.3, Ritz, J.1,3, Dranoff, G.1,3, Alyea, E.P.1 1Da-
na-Farber Cancer Institute, Boston, MA; 2Dana-Farber Cancer Institute,
Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA
We recently demonstrated that early post-transplant vaccination
of patients with myeloid leukemia with irradiated autologous tu-
mor cells, virally transduced to express the potent cytokine adju-
vant GM-CSF, is a promising approach to enhance anti-
leukemia immunity with minimal toxicity (Ho et al, PNAS
2009). Chronic lymphocytic leukemia (CLL) is an ideal disease
to extend this treatment approach since it is incurable by conven-
tional chemotherapy, is sensitive to graft-versus-leukemia effects,
and has readily harvestable leukemia cells. However, viral trans-
duction of lymphoid cells is inefficient, and GM-CSF-based cellu-
lar vaccines have thus far been unavailable for CLL. To address
this limitation, we manufactured K562 cells engineered to secrete
high and consistent levels of GM-CSF (10 micrograms GM-
CSF/106 cells/24 hours), and initiated a phase I study to test the
effects of a post-transplant vaccine consisting of 1 x 107 irradiated
autologous CLL cells together with an equal number of irradiated
bystander GM-K562 cells. CD19 + CD5 +CLL cells were har-
vested from patient peripheral blood or marrow and banked prior
to salvage chemotherapy. To date, we have enrolled 13 patients
with CLL, who had experienced a median of 4 prior therapies
(range 2-8). Median CLL marrow involvement at transplant was
10% (range \5-50%). Patients were conditioned with a fludara-
bine/busulfex-based reduced-intensity regimen prior to infusion
of peripheral blood stem cells from a matched related (4) or unre-
lated (9) donor, and received tacrolimus as GvHD prophylaxis
throughout the vaccination period. Starting on day 30-45, vaccines
were administered as a cycle of 6 vaccines (s.c./i.d., every week x 3,
then every 2 weeks x 3). Ten of 13 patients received at least one
vaccine, and 7 of 10 received 3 or more vaccines. Three of 13 de-
veloped graft-versus-host disease (GvHD) prior to day 45, preclud-
ing vaccination. Four of the 10 vaccinated subjects developed grade
II GvHD. None experienced unexpected toxicities to vaccines. At
a median follow-up of 1 year (range 0.5-2 years), 9 of 10 vaccinated
subjects remain free of disease, and 1 patient remains in partial re-
mission. Our studies reveal that reduced intensity transplant fol-
lowed by early CLL/GM-K562 vaccination is well-tolerated and
does not increase the expected rate of GvHD. Early clinical results
are promising and ongoing studies are assessing the effects of the
vaccination on the induction of immunity against recipient CLL
cells.AUTOIMMUNE DISEASE
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DENIALS OF TREATMENT COVERAGE BY HEALTH INSURANCE CARRIERS
RESTRICT PATIENT RECRUITMENT ON A RANDOMIZED CLINICAL TRIAL:
EXPERIENCE OF 95 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) EN-
ROLLED IN THE SCOT (SCLERODERMA: CYCLOPHOSPHAMIDE OR
TRANSPLANTATION) TRIAL
Sullivan, K.M.1, Seibold, J.R.2,Mineishi, S.2,Mayes,M.D.3, Hosing, C.4,
Nash, R.A.5, Wener, M.6, Csuka, M.E.7, Bredeson, C.7, Simms, R.8,
Ballen, K.9, Forman, S.10, St Clair, W.E.1, Furst, D.E.11 1Duke Univer-
sity Medical Center, Durham, NC; 2University of Michigan, Ann Arbor,
MI; 3University of Texas-Houston, Houston, TX; 4M.D. Anderson Can-
cer Center, Houston, TX; 5Fred Hutchinson Cancer Research Center, Se-
attle, WA; 6University of Washington, Seattle, WA; 7Medical College of
Wisconsin, Milwaukee, WA; 8Boston University, Boston, MA; 9Massa-
chusetts General Hospital, Boston, MA; 10City of Hope National Medical
Center, Duarte, CA; 11University of California, Los Angeles, CA
Background: Although health insurance coverage decisions can re-
strict recruitment on clinical trials, there are surprisingly few pub-
lished data measuring this effect.
Methods: Subjects with poor prognosis SSc were enrolled on the
ongoing SCOT trial comparing cyclophosphamide with autologous
stem cell transplant. Insurance submissions included evaluations
from SCOT rheumatology and BMT physicians, screening data,
protocol and consents approved by local IRBs, NIH and FDA and
supporting publications. Specific entry criteria and treatments are
further detailed at the study website (www.sclerodermatrial.org).
Results: Requests for coverage for 95 SCOT eligible patients (pts)
were submitted from the 7 BMT centers listed above to 49 health in-
surance plans (54 pts to 28 Blue Cross Blue Shield plans; 26 pts to 12
other commercial plans; and 15 pts to 9 governmental plans). At ini-
tial submission, 44 pts were approved and 51 (54%) were denied cov-
erage. Of the 51 subjects denied coverage, 15 did not appeal and
became ineligible for treatment randomization while 36 filed a first
appeal. Of these 36 pts, 23 were again denied while 13 (36%) were
approved on outside review. Of the 23 pts with first appeal denials,
10 did not file another appeal. Of the 13 filing a second appeal, 7
(54%) were approved. In total, 64/95 (67%) pts were approved on
initial or appeal reviews. The majority of denials were determina-
tions that protocol therapies were ‘‘experimental or investigational’’,
despite supplied published evidence that both SSc treatments yield
promising results (NEJM 2006; 354:2655 and Blood 2007;
110:1388). Time from application through appeals varied from 2-7
months, and for several subjects PFTs further declined during review
making them ineligible for randomization. Approval rates (initial ap-
plication + appeals) varied by carrier: 23/26 (88%) for non-Blue
plans; 33/54 (61%) for Blue plans; and 8/15 (53%) for governmental
plans. Remarkably, within the same plan, payment decisions for the
same protocol and the same type of pt were inconsistent or persistent
in denial despite reversals on outside expert review for prior pts.
Conclusions:Health insurer payment decisions can be arbitrary and
inconsistent. This is the first study with evidence that some insurers
delay and restrict patient access and recruitment on an NIH-spon-
sored randomized trial, thereby impeding clinical research and the
evidence needed to advance health care in America. Supported by
NIH award AI-05419.
AUTOLOGOUS TRANSPLANTS
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AN ALGORITHMIC APPROACH TO EVALUATE THE OPTIMAL USE OF
PLERIXAFOR (MOZOBIL) FOR AUTOLOGOUS HEMATOPOIETIC PE-
RIPHERAL BLOOD STEM CELL (PBSC) COLLECTIONS BASED ON PERIPH-
ERAL CIRCULATING CD34 COUNTS AND DAY ONE COLLECTION YIELD IN
PATIENTSWITHMULTIPLE MYELOMA (MM) AND LYMPHOMA (NHL, HD)
Abhyankar, S.H.1, Aljitawi, O.1, Ganguly, S.1, McGuirk, J.P.1,
DeJarnette, S.D.2,Merkel,D.A.2 1TheUniversity of KansasMedicalCen-
ter, Kansas City, KS; 2The University of Kansas Hospital, Kansas City, KS
Autologous PBSC transplantation is used as treatment for patients
with MM and lymphoma, but 25-35% of these patients fail to mobi-
lize a sufficient number of PBSC in the first mobilization attempt.
Plerixafor with G-CSF is now often used as a salvage mobilizing reg-
imen in patients failing first attempt with G-CSF alone.
Plerixafor (Mozobil) Guidance Algorithm
Evaluation Guidance
 Patients needing cells
for one transplant
(minimum 2.5 x10E6
CD34 cells/Kg) - mobilized
with G-CSF  Peripheral
CD34 checked on day 5
following 4 days of G-CSF.
 If CD34 number is\10 cells/ul,
give G-CSF post-procedure
and administer plerixafor that
evening. G-CSF will also be
given 1 hour pre-collection the
following morning.
 Patients needing more than
one transplant (minimum 5.0 x10E6
CD34 cells/Kg) mobilized
with G-CSF  Peripheral CD34
checked on day 5 following 4 days
of G-CSF.
 If CD34 number\20 cells/ul,
give G-CSF post procedure
and administer plerixafor that
evening. G-CSF will be given
1 hour pre-collection the
following morning.
 The first day collected product
contains LESS THAN one-half
of the desired dose of 2.5 x 10E6
CD34/Kg or 5.0 x 10E6 CD34/Kg.
 Give plerixafor that evening.
G-CSF will also be given
1 hour pre-collection the
following morning.
 Patients pretreated with lenalidomide
(more than 4 cycles).  Patients
with delayed count recovery from
prior therapy.  Other reasons for
high mobilization failure rate.
 Four days of G-CSF, then
plerixafor given on the fourth
evening. G-CSF will be given
1 hour pre-collection the
following morning.
* G-CSF is given at 10 mcg/kg for four days for mobilization; ** Plerixafor
is given at 240 mcg/kg per treatment.
Oral Presentations S165Our goal was to reduce the number of collections andmobilization
failures to achieve the desired CD34 dose, with optimal use of plerix-
afor. Options were to use it for all patients or to develop an algorithm
of when to add it to the primary mobilization regimen. Plerixafor is
not warranted for every patient due to its high cost; hence usage
that is fiscally beneficial was developed. This algorithm evaluates fac-
tors needed to use plerixafor as described in the table below. All col-
lections performed were 4-6 blood volume procedures.
FromApr. to Sept. 2009, 44 patients (Ages: 30-69;Dx: 22 MMand
22 NHL, HD; Sex: 26 M and 18 F) were considered for plerixafor
using this algorithm. Fifteen (Ages: 38-67; Dx: 7 MM and 8 NHL,
HD; Sex: 10 male and 5 female) of the 44 patients (34%) were given
plerixafor. Of the 15 patients, 5 (33%) were given plerixafor due to
low peripheral CD34 counts on day 1; 6 (40%) were given plerixafor
due to a collection of less than one-half of the desired collection goal
on day 1; and 4 (27%) were given plerixafor up-front. Fourteen of the
15 patients (93%) were able to collect during the first mobilization
attempt using this algorithm. The average number of collection
days for the plerixafor patients was 2.3 compared to 1.7 for the rest
of the patients not given plerixafor. Collectively, the number was
1.91 collection days per patient for time span evaluated. In years
2007-2008, the number of collection days was 2.68 days per patient,
27 of 137 patients (19.7%) required remobilization and 11 of 137
(8%) failed mobilization.
This approach has the potential to reduce the overall cost of PBSC
collections by reducing the number of collection days and avoiding
remobilization in a significant percentage of patients. Each extra
day of collection and each remobilization is an additional $8,000
to $10,000 expense for the patient. Other concerns are the possible
need for platelet transfusions with multiple collections and the pos-
sible delay in transplant increasing the risk of disease relapse. This
algorithmic approach providing for the optimal use of plerixafor
needs to be further evaluated with a larger number of patients.29
CONVENTIONAL CHEMOTHERAPY FOLLOWED BY CONSOLIDATION
WITH AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION VS CHEMO-
THERAPY ALONE IN HIV+ PATIENTS WITH LARGE B CELL LYMPHOMA
(LBCL) IN FIRST COMPLETE REMISSION (CR). A RETROSPECTIVE ANAL-
YSIS ON BEHALF OF THE EBMT LYMPHOMA WORKING PARTY AND THE
GESIDA/PETHEMA REGISTRY OF HIV+ PATIENTSWITH NON-HODGKIN’S
LYMPHOMA (NHL)
Balsalobre, P.1, Berenguer, J.2, Miralles, P.2, Serrano, D.1, Ribera, J.M.3,
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Pintado, V.13, Sureda, A.4, Diez-Martin, J.L.1 1Hospital General Uni-
versitario Gregorio Maran˜on, Madrid, Spain; 2Hospital General Univer-
sitario Gregorio Maran˜on, Madrid, Spain; 3 ICO-Hospital Universitari
Germans Trias i Pujol, Badalona, Barcelona, Spain; 4EBMT, Barcelona,
Spain; 5Hospital La Paz, Madrid, Spain; 6Centro di Riferimento Oncolo-
gico, Aviano, Italy; 7Hospital Carlos III,Madrid, Spain; 8Centre Hospital-
ier Universitaire Vaudois, Laussane, Switzerland; 9Hospital Donostia,
San Sebastian, Spain; 10Hopital Victor Dupouy, Argenteuil, France;
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taires Saint-Luc, Brussels, Belgium; 13Hospital Ramon y Cajal, Madrid,
Spain
Little is known about the additional benefit of Autologous Stem
Cell Transplantation (ASCT) as consolidation treatment of NHL
in 1st CR in HIV+ patients. We herein report a comparative analysis
of HIV+ patients with a LBCL treated with chemotherapy (chemo)
followed by ASCT and a matched cohort of HIV+ patients treated
with chemo alone.
Methodology:Retrospective, registry-based, matched cohort study.
ASCT cohort: patients with diffuse large B-cell (DLBC) or plasma-
blastic NHL treated with ASCT in 1st CR after standard chemo and
reported to the EBMT Registry. Chemo cohort: For each patient
within the ASCT cohort we selected two controls from the HIV+
patients with NHL GESIDA/PETHEMA registry. Patients in
both cohorts were in 1st CR following front-line or rescue (for
partially responding patients) chemo and were matched according
to histology, IPI and the use of Rituximab.We compared overall sur-
vival (OS), disease free survival (DFS) and cumulative incidence (CI)
of relapse between both cohorts. These primary outcomes were
defined according to the EBMT. OS was computed from diagnosis
while DFS and CI of relapse were computed from 3 weeks after
the last standard chemo cycle administered (end of chemo).
Results:The ASCT cohort included 10 patients diagnosed between
1999 and 2005. The Chemo cohort included 20 patients, 16 diag-
nosed between 1999 and 2005. Both cohorts were comparable for
the main clinical and patient features (Table 1). The median (range)
follow-up (FU) time since the end of chemo for surviving patients
was 56 months (mo) (24-106) in the ASCT cohort vs 37 mo (8-
107.5) in the Chemo cohort; P5.28. Five years (yr) OS for the
ASCT cohort and the Chemo cohort were 68.5% [CI95%: 39-98]
and 46.5% [CI95%: 18-75], respectively; P5.6. Three yr DFS for
the ASCT cohort and the Chemo cohort were 70% [CI95%: 41.5-
98.5] and 59.5% [CI95%: 29-86]; respectively; P5.4. The CI of re-
lapse in the ASCT cohort and the Chemo cohort were 21% [CI95%:
0-47] and 27% [CI95%: 2-51], respectively; P5.8
Conclusions: In this retrospective registry-based, matched co-
hort study of HIV+ patients with large B-cell NHL we found
a non-significant effect of ASCT as consolidation treatment in
1st CR patients, in terms of survival and relapse incidence. Nev-
ertheless, due to the observed favorable tendency, future analysis
including a higher number of patients and, eventually, random-
ized clinical studies, should be performed to further clarify these
observations.Table 1. Patients and transplant features
ASCT cohort Chemo cohortn5 10 n5 20Prior AIDS defining disease 43% 30% p5NS
Age at lymphoma diagnosis:
median (range)
40 (34-60.5) 43.5 (30-56.5) p5NSMale sex 7 (70%) 14 (70%) p5NS
Diffuse large B cell /
Plasmablastic
8 (80%) / 2
(20%)18 (90%) / 2
(10%)p5NSIPI at diagnosis (.2) 7 (70%) 14 (70%) p5NS
Ann Arbor stage at
diagnosis (.II)
9 (90%) 16 (80%) p5NSRituximab use 5 (50%) 10 (50%) p5NS
Number of treatment lines:
median (range)
1 (1-2) 1 (1-2) p5NSMonths from diagnosis to end
of chemo: median (range)5.8 (3.5-11) 4.3 (2.4-7.4) p5NS
